Physician profile
Wayne L Scott
NPI 1942274980
$7,092.77
in general payments reported to CMS, 2019-2025
23 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $984 · 2021: $596 · 2022: $1,203 · 2023: $734 · 2024: $2,244 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $3,650.78 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,054.38 | 2022-2025 | Xen Glaucoma Treatment System |
| Alcon Vision LLC | $685.55 | 2021-2025 | Hydrus Microstent, Clareon, Centurion |
| Genentech USA, INC. | $249.91 | 2022-2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $215.98 | 2019-2025 | Eylea Hd |
| Amgen INC. | $174.59 | 2024 | Tepezza |
| Ivantis, INC | $169.76 | 2020-2021 | |
| Allergan, INC. | $161.23 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $143.02 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $122.58 | 2024-2025 | Xiidra, Miebo |
| Apellis Pharmaceuticals, INC. | $67.89 | 2024-2025 | Syfovre |
| Dompe US, INC. | $58.18 | 2024-2025 | Oxervate |
| New World Medical,INC. | $56.80 | 2022-2023 | |
| Carl Zeiss Meditec Cataract Technology INC. | $42.29 | 2020 | |
| Oyster Point Pharma, INC. | $36.03 | 2022-2023 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $34.90 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $32.66 | 2024 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $32.09 | 2022 | |
| Genentech, INC. | $29.71 | 2023 | Vabysmo |
| Thea Pharma INC. | $22.76 | 2025 | Iyuzeh |
| Astellas Pharma US INC | $20.88 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.45 | 2019 | |
| Biotissue Holdings INC. | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.